Delivery Order 36F79719D0153-36C26124N0260
Award Date 11/20/23
Potential Completion Date 12/4/23
Potential Value $12K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16 awarded a $40,668.40 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule to Genzyme Corporation for emergency Caprelsa (vandetanib) medication. Genzyme Therapeutics Division, a division of Sanofi Genzyme, will provide the medication on a firm fixed price basis, with completion by October 30, 2020. The delivery order was awarded on May 28, 2020 under GSA Schedule...
- This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21 (VISN 21) to Genzyme Corporation, doing business as Sanofi Genzyme, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The $89,094.00 order is for the delivery of various specialty pharmaceutical products, including Eliglustat (Cerdelga), Lemtrada, and Caprelsa (vandetanib), to support treatment programs for veterans. Genzyme...
- The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order contract to Genzyme Corporation, a division of Sanofi Genzyme, to provide the drug CERDELGA. The contract has a potential value of $106,912.80 and a completion date of March 31, 2019. Genzyme is the prime contractor on this award, which was placed against the company's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a multiple award schedule managed by the VA. The...
- This federal contract award is for the delivery of Eliglustat (Cerdelga) 84mg oral capsules to the Puget Sound VA Health Care System. The $144,553.36 firm fixed price delivery order was issued against Genzyme Corporation's Pharmaceuticals and Drugs GSA Schedule contract (FSS-61-IB) with the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). Genzyme Corporation, doing business as Sanofi Genzyme, is the prime contractor for this order, with no set-aside designation...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $212,340.40 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract to Genzyme Corporation for the bulk purchase of 84mg oral capsules of Eliqlustat (Cerdelga). Performance will take place in Cambridge, Massachusetts with no set-aside designation applied. Genzyme Therapeutics Division, doing business as Sanofi Genzyme, will serve as the...
- Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $50,142.96 firm fixed price delivery order against the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) to provide LEMTRADA for the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1. Performance will take place in Cambridge, Massachusetts through September 30, 2021. No set-aside designation was used for this award issued...
- This firm fixed-price delivery order was awarded by the Department of Veterans Affairs' (VA) Veterans Health Administration (VHA) to Genzyme Corporation, doing business as Sanofi Genzyme, for the pharmaceutical product Eliglustat (Cerdelga 84mg) under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) contract. The order has a ceiling value of $246,001.38 and a performance period ending on October 26, 2023. Genzyme serves as the prime contractor, with no set-aside designation applied. This...
- This is a federal contract award to Genzyme Corporation, doing business as Sanofi Genzyme, by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The award has a ceiling value of $161,979.21 and is a delivery order under Genzyme's existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract valued at $659 million. The delivery order is for the specialty pharmaceutical product Cerdelga (eliglustat), which is used to treat Gaucher's disease. The...
- Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $204,743.40 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) prime vendor contract vehicle. The order calls for the delivery of the drug eliglustat to the Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 in Cambridge, Massachusetts by February 25, 2021. No set-aside designation was applied to...
- Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $17,830.87 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The firm fixed price order is for the provision of eliglustat to the agency's Cambridge, Massachusetts facility, with an anticipated completion date of April 19,...